awmsg logo



nalmefene (Selincro®)


Reference No. 1259

Publication date:
27/02/2014


Last review date:
17/02/2017

Appraisal information

nalmefene (Selincro®) 18 mg film-coated tablet


Company: Lundbeck Ltd
BNF category: Central nervous system
NMG meeting date: 27/11/2013
AWMSG meeting date: 15/01/2014
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 0414
Ministerial ratification: 26/02/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA325) NICE GUIDANCE ISSUED NOVEMBER 2014 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Nalmefene (Selincro®) is recommended as an option for use within NHS Wales for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL) without physical withdrawal symptoms and who do not require immediate detoxification. Nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption. Nalmefene should be initiated only in patients who continue to have a high DRL two weeks after initial assessment.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download